Nativis Research Partner to Present at COGNO Conference in Australia

Nativis Research Partner Publishes Findings on New Brain Cancer Treatment in Journal of Neuro-Oncology

Nativis Inc., a clinical stage life science bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced the peer reviewed publication of a research paper in the Journal of Neuro-Oncology (JNO) on a novel technology to treat brain cancer.

Leading the efforts behind the research paper were Charles Cobbs, MD, Chair of the Nativis Medical & Scientific Advisory Board and Director of the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment at Swedish Neuroscience Institute, and Michael Prados, MD, Director of Translational Research at the Department of Neurological Surgery at the University of California, San Francisco.  The article in JNO provided data by the research team identifying the significance of using the Nativis Voyager® technology electromagnetic fields (EMF) in the ultra-low radio frequency energy (ulRFE™) range to affect brain cancer cells at the molecular level.  This technology was used to demonstrate the specificity and cellular effects on human derived glioblastoma (GBM) brain cancer cells. It was shown that this technology can specifically knock down EGFR gene expression, with resulting biological effects, in human primary (GBM) cells by exposing these cells to physical-EGFR siRNA and RFE-siEGFR signal.  EGFR is a commercially proven target with multiple bio-pharmaceutical products approved to treat several different types of cancer.

“Brain cancer is known to be one of the most difficult cancers to treat due to the blood-brain barrier that makes delivery of pharmaceutical treatment difficult and ineffective,” said Dr. Cobbs.  “The Nativis Voyager technology delivers treatment via electronic signal, therefore by-passing the problems of delivering standard chemotherapy, and other drug treatment and the accompanying harsh physical effects that patients suffer.”

“We continue to be encouraged about our Voyager technology to treat brain cancer as this research paper demonstrates,” said Chris Rivera, Chief Executive Officer of Nativis. “These findings are the first, to our knowledge, that demonstrate specific molecular gene knockdown using ulRFE energy. Our strategy is to replicate the biological effects of commercially approved drugs and other therapeutic agents with our ulRFE technology.  We have several research collaborations in the US and globally for work on human health, as well as other markets and sectors, including veterinary and plant science.  It appears that our technology may be utilized in many ways and over multiple platforms to treat disease and other maladies.  With the successful development of our ulRFE technology for the treatment of glioblastoma multiforme (GBM), a very complex and difficult area to treat, the impact for patients with GBM and other diseases could be monumental.”

Further comments were made by Nativis Medical and Scientific Board Member Victor Levin, MD, Founder of the Society of Neuro Oncology (SNO) and Emeritus Professor of Neuro-Oncology at The University of Texas, M.D. Anderson Cancer Center.  “This research is very important as it provides additional support for the importance of this technology to patients with CNS cancers and other tumors. The application of this research provides, for the first time, the possibility of treating human diseases with low energy electromagnetic field technology that can reduce the production of signaling proteins within tumor cells. Given that new drug development is almost absent for CNS cancers and those available today are of limited efficacy and produce a wide range of side effects making creating effective drug combinations difficult, the RFE approach is truly a bright light for patients in the future. This is true for brain cancer and likely equally true for other diseases affecting the brain.  The implications and possible uses of this novel approach cannot be underestimated,” Dr. Levin added.

The abstract of this paper can be seen at

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, often resulting in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.

Investor Relations Contact:

Lee Roth / Tram Bui /

646-536-7012 / 7035


Media Relations Contact:

Aaron Blank / Amber Benson /


Back to News